Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
about
Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipientsNovel antifungal agents: a patent review (2013 - present).Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.Natural product and natural product derived drugs in clinical trials.Antifungals: Mechanism of Action and Drug Resistance.New facets of antifungal therapy.The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.Echinocandins in antifungal pharmacotherapy.Drugs in Clinical Development for Fungal Infections.Antifungal Activity of SCY-078 and Standard Antifungal Agents Against 178 Clinical Isolates of Resistant and Susceptible Candida Species.Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.New Horizons in Antifungal Therapy.Antifungals discovery: an insight into new strategies to combat antifungal resistance.De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis.In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.
P2860
Q28084643-776D197C-824C-4357-ACE1-617E368B7DB7Q30239745-681A1E74-526C-4EF1-AAC2-63E8C7E55FB1Q35746106-57A1BA8F-CFED-4426-9D4F-9F0C447B990CQ37720794-05206576-FAFF-426E-B79F-DFB7DB355FCCQ38247457-B21F2C20-D36D-41F3-AD54-43F2CFE01577Q38684281-75E38CFF-A977-431B-B788-CDB63C81356CQ38797864-77AC5445-C756-4E67-8957-2FB0921C793DQ38949297-A0EFEE62-0283-44C0-9B11-39883F76D49EQ39458862-568D6C1F-55BC-4B06-B5A8-AA4BC4EB68A9Q40070714-E2C6BCCA-9E65-4E58-A4B0-D2DF53DBCEB3Q40085154-00D6E780-FE54-4750-9884-1C4FECF992B0Q40202924-DF36E09C-C8D6-4F98-98D4-A470A9A8AF84Q40340923-62EF7F5E-C88C-434F-AAB0-46140A139327Q42319613-42A17456-DDBC-4728-BFD5-7EA2A8948A04Q47410811-64D8CCF1-7A99-4846-8F4C-8F3B996002CEQ48149179-5A1A2BFA-171E-4E0D-A0EB-9FBD1A54D8F3Q50122600-1E6C3BFE-3D45-44E7-97EF-7DE9D1515D08Q50284921-0D7C9B04-7072-4A06-B3A6-096A50225700Q52611985-B7E6689F-1B1F-4961-B47A-52508E6BF524Q53789385-4D9927DE-2358-4FA9-8C5D-F1C4C3586E4A
P2860
Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Enfumafungin derivative MK-311 ...... Aspergillus species isolates.
@en
type
label
Enfumafungin derivative MK-311 ...... Aspergillus species isolates.
@en
prefLabel
Enfumafungin derivative MK-311 ...... Aspergillus species isolates.
@en
P2093
P2860
P356
P1476
Enfumafungin derivative MK-311 ...... Aspergillus species isolates.
@en
P2093
Cristina Jiménez-Ortigosa
David S Perlin
Mary R Motyl
Padmaja Paderu
P2860
P304
P356
10.1128/AAC.02145-13
P407
P577
2013-12-09T00:00:00Z